<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188731</url>
  </required_header>
  <id_info>
    <org_study_id>734548PW (EC | H2020 | RIA)</org_study_id>
    <nct_id>NCT03188731</nct_id>
  </id_info>
  <brief_title>ZIKAlliance Pregnant Women Cohort</brief_title>
  <acronym>ZIKAlliancePW</acronym>
  <official_title>Pregnant Women (PW) Cohort for Evaluation of Risks of Congenital Malformations and Other Adverse Pregnancy Outcomes After Zika Virus Infection (Part of ZIKAlliance)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Heidelberg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZIKAlliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal University of Bahia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade Federal de Goias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Carabobo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Industrial de Santander</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sosecali Hospital, Guyaquil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tropical Medicine Institute Pedro Kourí, Cuba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mexican National Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Heidelberg Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV)
      infections in pregnancy and congenital malformations. We will estimate the absolute and
      relative risks of congenital malformations and other adverse outcomes of pregnancy among
      women who become infected with ZIKV during pregnancy compared to uninfected pregnant women,
      also leading to further validation of the Congenital Zika Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV)
      infections in pregnancy and congenital malformations. We will estimate the absolute and
      relative risks of congenital malformations and other adverse outcomes of pregnancy among
      women who become infected with ZIKV during pregnancy compared to uninfected pregnant women,
      also leading to further validation of the Congenital Zika Syndrome.

      We will also determine the ZIKV maternal to child transmission rate and evaluate co-factors
      or effect modifiers that account for the large variability seen in the preliminary absolute
      risk estimates derived from population figures and reporting of microcephaly in different
      states in Brazil and across Latin America.

      We will carry out a pregnant women (PW) multicentre cohort study in areas across Latin
      America and the Caribbean. Women will be enrolled early in pregnancy and followed every 4
      weeks, in connection with their routine antenatal care visits. At each visit, urine and blood
      samples will be collected, tested and stored.

      Among PW reporting recent or current undifferentiated fever/rash syndrome at any point in
      time, the acute illness episode will be characterized in greater detail. PW with suspected
      ZIKV infection (i.e. meeting the Pan American Health Organization (PAHO) clinical case
      definition) during pregnancy will be managed according to national protocols. Irrespective of
      symptoms, pregnant women will be followed prospectively and revisited at birth (or after
      abortion) for a detailed documentation of the outcome of their pregnancy.

      Live newborns will receive a detailed neonatal examination. In the course of examination of
      the newborns, biological samples will be collected and stored. Other potential causes of
      congenital abnormalities (TORCHS infections in the mother, toxic substances, chromosomal
      abnormalities), and potential effect modifiers (for example past flavivirus
      infections/vaccinations, socio-economic status) will also be assessed.

      With appropriate counselling and consent, biological samples of newborns with severe
      abnormalities, deceased newborns, stillborn babies, and aborted foetuses from ZIKV-infected
      mothers will be collected to help elucidate the aetiological contribution of ZIKV in
      neurological and other congenital malformations.

      Children of women infected with ZIKV during pregnancy - and a subset of the children born to
      uninfected women - will be followed prospectively after birth for the assessment of
      neuro-developmental milestones (separate protocol).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Congenital Abnormalities</measure>
    <time_frame>At birth</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Zika Virus</condition>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Pregnant Women</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Hair, Urine, Vaginal fluids, Saliva, Semen
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant Women
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 16 years old

          -  Pregnancy status confirmed

          -  Within first or second trimester or first month of marked transmission season

        Exclusion Criteria:

          -  Planing to leave area

          -  Unable to attend follow-up visits

          -  Unable to undergo venipuncture

          -  Participates in another pregnant women study for ZIKA

          -  Unable to consent without legal guardian
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Jänisch</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sosecali Ltd. (SOSE)</name>
      <address>
        <city>Guaqui</city>
        <country>Bolivia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSERM</name>
      <address>
        <city>Santa Cruz</city>
        <country>Bolivia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal University of Bahia (UFB)</name>
      <address>
        <city>Bahia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal University of Goias</name>
      <address>
        <city>Goiás</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Oswaldo Cruz (FIOCRUZ)</name>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Oswaldo Cruz (FIOCRUZ)</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Industrial University of Santander (UIS)</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pedro Kouri Institute (IPK)</name>
      <address>
        <city>Havana</city>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSERM</name>
      <address>
        <city>Pointe-à-Pitre</city>
        <country>Guadeloupe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMSS Mexico (IMSS)</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Public Health (INSP)</name>
      <address>
        <city>Mérida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad de Carabobo / UMC Groningen (UMCG)</name>
      <address>
        <city>Valencia</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bolivia</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Cuba</country>
    <country>Guadeloupe</country>
    <country>Mexico</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Heidelberg Medical Center</investigator_affiliation>
    <investigator_full_name>Thomas Jaenisch</investigator_full_name>
    <investigator_title>Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>ZIKA</keyword>
  <keyword>Dengue</keyword>
  <keyword>Chikungunya</keyword>
  <keyword>Pregnant Women</keyword>
  <keyword>Pregnant Woman</keyword>
  <keyword>ZIKV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zika Virus Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The ZIKAlliance birth cohort is part of the 3 EC-funded Zika consortia. The data are intended to be shared after the individual cohort data is analyzed and published.
The ZIKAlliance birth cohort is part of the WHO-moderated IPD meta-analysis Consortium. The data are intended to be shared after the individual cohort data is analyzed and published.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

